Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple My...

Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma  The ASCO Post

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refrac...

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial  The Lancet

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leuk...

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leukemia  Nature

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma - Targeted Oncology

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma  Targeted Oncology

Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL - OncLive

Tafasitamab/Lenalidomide/R-CHOP Improves PFS vs R-CHOP Alone in First-Line DLBCL  OncLive

Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma - CancerNetwork

Cilta-cel Boosts Survival in Lenalidomide-Refractory Multiple Myeloma  CancerNetwork

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line ...

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line  AJMC

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM - Hematology A...

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM  Hematology Advisor

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma...

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma  The ASCO Post

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): ...

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial  The Lancet

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: A...

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses | Blood Cancer Journal  Nature

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma - OncLive

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma  OncLive

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with h...

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial  Nature

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractor...

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma  The ASCO Post

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in ...

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma  OncLive

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and...

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study  Nature

Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymph...

Addition of Epcoritamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma  The ASCO Post

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Dia...

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma  OncLive

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospectiv...

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma  Nature

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma - ...

Tafasitamab Plus Rituximab and Lenalidomide Wins Japanese Approval for R/R Follicular Lymphoma  OncLive

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/...

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/R FL  Lymphoma Hub

Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lympho...

Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lymphoma  OncLive

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma - OncLive

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma  OncLive

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma -...

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma...

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma  OncLive

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymph...

Addition of Tafasitamab to Lenalidomide Plus Rituximab in Relapsed or Refractory Follicular Lymphoma  The ASCO Post

Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma - O...

Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma  OncLive

Daratumumab–lenalidomide–dexamethasone (DRd) vs. lenalidomide–dexamethasone in patients with rela...

Daratumumab–lenalidomide–dexamethasone (DRd) vs. lenalidomide–dexamethasone in patients with relapsed/refractory multiple myeloma — Polish early real-world experience following DRd reimbursement in the B.54 drug program | Piotrowska | Acta Hae  Via Medica Journals

Lenalidomide-induced type II Kounis syndrome: a case report - Frontiers

Lenalidomide-induced type II Kounis syndrome: a case report  Frontiers

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate i...

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM  ASCO Daily News

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma - OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma  OncLive

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma - The ASCO Post

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma  The ASCO Post

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple My...

Lenalidomide-Associated Liver Injury With Features of Vanishing Bile Duct Syndrome in Multiple Myeloma  Cureus

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma - OncLive

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma  OncLive

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma - OncLive

Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma  OncLive

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, New...

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma  OncLive

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions ...

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma  OncLive

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL - Lymphoma Hub

Real-world experience of tafasitamab and lenalidomide for the treatment of R/R DLBCL  Lymphoma Hub

Zanubrutinib + rituximab + lenalidomide in de novo DLBCL: Phase II results - Lymphoma Hub

Zanubrutinib + rituximab + lenalidomide in de novo DLBCL: Phase II results  Lymphoma Hub

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple ...

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma  Pharmacy Times

Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules - Lupin | Press Release - lupin.com

Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules - Lupin | Press Release  lupin.com

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoc...

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review  Frontiers

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-D...

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-DRd in Italy: A Multi-Criteria Decision Framework  European Medical Journal

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory ...

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma  OncLive

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lympho...

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma  OncLive

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL - Lymphoma Hub

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL  Lymphoma Hub

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly D...

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma  OncLive

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide ...

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide  Pharmacy Times

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma - Targeted Oncology

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma  Targeted Oncology

Study Identifies Recommended Lenalidomide Maintenance Dose for Patients with Multiple Myeloma - D...

Study Identifies Recommended Lenalidomide Maintenance Dose for Patients with Multiple Myeloma  Docwire News

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multipl...

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL - OncLive

sBLA Submission Planned for Epcoritamab/Rituximab/Lenalidomide in R/R FL  OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myel...

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myeloma  Pharmacy Times

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myelom...

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma  OncLive

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Fo...

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT  OncLive

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligibl...

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma  OncLive

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamet...

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GE  The Lancet

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety - Pharm...

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety  Pharmacy Times

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and...

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation  Nature

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myel...

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myeloma  OncLive

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Dia...

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Diagnosed Multiple Myeloma  Pharmacy Times

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA lon...

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia  Nature

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Fo...

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma  OncLive

Does Revlimid® Warrant a Change in Standard of Care for Smoldering Multiple Myeloma - Docwire News

Does Revlimid® Warrant a Change in Standard of Care for Smoldering Multiple Myeloma  Docwire News

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with ...

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL  Lymphoma Hub

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL - OncLive

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL  OncLive

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies - CancerNetwork

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies  CancerNetwork

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular ...

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma  Pharmacy Times

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL? - Lymphom...

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?  Lymphoma Hub

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphom...

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma  OncLive

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor ...

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial  Nature

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of eld...

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma  Nature

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments - CancerNetwork

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments  CancerNetwork

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Admini...

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Administration for adult patients with R/R DLBCL  Lymphoma Hub

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coh...

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coherent Market Insights  BioSpace

FDA Accepts Amneal’s Abbreviated New Drug Application for Lenalidomide Capsules - Docwire News

FDA Accepts Amneal’s Abbreviated New Drug Application for Lenalidomide Capsules  Docwire News

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma - Oncology ...

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma  Oncology News Central

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety...

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database | Blood Cancer Journal  Nature

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - The New England J...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  The New England Journal of Medicine

HRQOL Improved With Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma - CancerNetwork

HRQOL Improved With Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma  CancerNetwork

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecu...

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes  Nature

Phase III inMIND trial: Efficacy and safety of tafasitamab plus lenalidomide and rituximab for R/...

Phase III inMIND trial: Efficacy and safety of tafasitamab plus lenalidomide and rituximab for R/R FL  Lymphoma Hub

Indatuximab Ravtansine With Dexamethasone Plus Lenalidomide or Pomalidomide in Multiple Myeloma -...

Indatuximab Ravtansine With Dexamethasone Plus Lenalidomide or Pomalidomide in Multiple Myeloma  Docwire News

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomi...

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma  Nature

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma - The New England Journal ...

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma  The New England Journal of Medicine

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths - AJMC

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths  AJMC

Real-World Data Support Rituximab Plus Lenalidomide in NHL - AJMC

Real-World Data Support Rituximab Plus Lenalidomide in NHL  AJMC

Lupin Gets US FDA Approval For Generic Lenalidomide Capsules - NDTV Profit

Lupin Gets US FDA Approval For Generic Lenalidomide Capsules  NDTV Profit

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelod...

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial  Nature

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradat...

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation  Nature

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma:...

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial  Nature

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma - The New England J...

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma  The New England Journal of Medicine

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America - The New England ...

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America  The New England Journal of Medicine

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer...

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer Journal  Nature

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide - Nature

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide  Nature

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma - The New England Jo...

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma  The New England Journal of Medicine

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma - Onc...

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma  OncLive

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-...

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial  Nature